These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38493348)

  • 21. The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization.
    Weissler EH; Aboyans V; Bauersachs R; Brodmann M; Nikol S; Debus S; Patel MR; Jones WS
    JACC Cardiovasc Interv; 2021 Apr; 14(7):796-802. PubMed ID: 33826501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
    Krantz MJ; Debus SE; Hsia J; Patel MR; Anand SS; Nehler MR; Hess CN; Capell WH; Bracken T; Szarek M; Mátyás L; Krievins DK; Nault P; Stefanov S; Haskell LP; Berkowitz SD; Muehlhofer E; Hiatt WR; Bauersachs RM; Bonaca MP
    Eur Heart J; 2021 Oct; 42(39):4040-4048. PubMed ID: 34430972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study.
    Ji Y; Wang B; Wu G; Zhang Y; Wang Q; Zhou M
    Ther Adv Chronic Dis; 2023; 14():20406223231213262. PubMed ID: 38085917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization.
    Jones WS; Patel MR; Tsai TT; Go AS; Gupta R; Hedayati N; Ho PM; Jazaeri O; Rehring TF; Rogers RK; Shetterly SM; Wagner NM; Magid DJ
    Am Heart J; 2015 Aug; 170(2):400-8. PubMed ID: 26299239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Voyager PAD Trial - New Path for Post-revascularisation PAD Patients.
    Debus ES; Nehler MR;
    Eur J Vasc Endovasc Surg; 2020 May; 59(5):699-700. PubMed ID: 32307302
    [No Abstract]   [Full Text] [Related]  

  • 26. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
    Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI; Yusuf S; Anand SS
    JAMA Cardiol; 2021 Jan; 6(1):21-29. PubMed ID: 32997098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. External applicability of the COMPASS trial: the Western Denmark Heart Registry.
    Würtz M; Olesen KKW; Thim T; Kristensen SD; Eikelboom JW; Maeng M
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):192-199. PubMed ID: 30916315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.
    Qamar A; Morrow DA; Creager MA; Scirica BM; Olin JW; Beckman JA; Murphy SA; Bonaca MP
    Vasc Med; 2020 Apr; 25(2):124-132. PubMed ID: 32000630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inter-core lab variability in analyzing quantitative coronary angiography for bifurcation lesions: a post-hoc analysis of a randomized trial.
    Grundeken MJ; Ishibashi Y; Généreux P; LaSalle L; Iqbal J; Wykrzykowska JJ; Morel MA; Tijssen JG; de Winter RJ; Girasis C; Garcia-Garcia HM; Onuma Y; Leon MB; Serruys PW
    JACC Cardiovasc Interv; 2015 Feb; 8(2):305-314. PubMed ID: 25700754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial.
    Hsia J; Szarek M; Anand S; Patel MR; Debus S; Berkowitz SD; Muehlhofer E; Haskell LP; Bauersachs RM; Bonaca MP
    J Am Coll Cardiol; 2021 Aug; 78(7):757-759. PubMed ID: 34384556
    [No Abstract]   [Full Text] [Related]  

  • 31. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
    Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
    J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plaque Composition in the Proximal Superficial Femoral Artery and Peripheral Artery Disease Events.
    McDermott MM; Kramer CM; Tian L; Carr J; Guralnik JM; Polonsky T; Carroll T; Kibbe M; Criqui MH; Ferrucci L; Zhao L; Hippe DS; Wilkins J; Xu D; Liao Y; McCarthy W; Yuan C
    JACC Cardiovasc Imaging; 2017 Sep; 10(9):1003-1012. PubMed ID: 27838307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient Characteristics in the Recording Courses of Vascular Diseases (Reccord) Registry: Comparison with the Voyager Pad Endovascular Cohort.
    Czihal M; Malyar N; Stausberg J; Hoffmann U;
    J Cardiovasc Dev Dis; 2023 Mar; 10(3):. PubMed ID: 36975879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Who may benefit from low-dose rivaroxaban plus aspirin? Practical implications for outpatients with cardiovascular disease.
    De Luca L
    Pol Arch Intern Med; 2023 Oct; 133(10):. PubMed ID: 37738024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study.
    Mohammedi K; Woodward M; Hirakawa Y; Zoungas S; Colagiuri S; Hamet P; Harrap S; Poulter N; Matthews DR; Marre M; Chalmers J;
    Cardiovasc Diabetol; 2016 Sep; 15(1):129. PubMed ID: 27590190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(18):1-88. PubMed ID: 23074395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antithrombotic therapy after peripheral revascularization].
    Espinola-Klein C
    Dtsch Med Wochenschr; 2021 Feb; 146(3):136-140. PubMed ID: 33513644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of routine coronary catheterization in low extremity artery disease undergoing percutaneous transluminal angioplasty: study protocol for a multi-center randomized controlled trial.
    Chen IC; Lee CH; Chao TH; Tseng WK; Lin TH; Chung WJ; Li JK; Huang HL; Liu PY; Chao TK; Chu CY; Lin CC; Hsu PC; Lee WH; Lee PT; Li YH; Tseng SY; Tsai LM; Hwang JJ
    Trials; 2016 Feb; 17(1):112. PubMed ID: 26927298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of coronary artery disease in patients undergoing peripheral artery disease surgery.
    Hur DJ; Kizilgul M; Aung WW; Roussillon KC; Keeley EC
    Am J Cardiol; 2012 Sep; 110(5):736-40. PubMed ID: 22633203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.